<DOC>
	<DOCNO>NCT00129766</DOCNO>
	<brief_summary>The primary objective study compare safety efficacy motavizumab palivizumab administer monthly intramuscular ( IM ) injection reduction incidence RSV hospitalization among child high risk serious RSV disease . A secondary objective compare incidence medically-attended low respiratory infection ( LRIs ) treatment group .</brief_summary>
	<brief_title>Study MEDI-524 ( Motavizumab ) Prophylaxis Serious Respiratory Syncytial Virus ( RSV ) Disease High-Risk Children</brief_title>
	<detailed_description>A randomized , double-blind , palivizumab-controlled , multi-center , multi-national trial conduct 2 Northern Hemisphere RSV season intervene season Southern Hemisphere . Each child participate single RSV season . Approximately 6,600 child risk serious RSV disease randomize 1:1 ratio receive either 15 mg/kg palivizumab motavizumab IM injection every 30 day total 5 dos .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>24 month age young randomization ( child must randomize his/her 24month birthday ) diagnosis chronic lung disease ( CLD ) prematurity require medical intervention/management ( i.e. , supplemental oxygen , bronchodilator , diuretic ) within 6 month randomization OR : 35 week gestational age less birth 6 month age young randomization ( child randomize his/her 6month birthday ) Hospitalization time randomization ( unless discharge anticipate within 10 day ) Mechanical ventilation mechanical support ( include continuous positive airway pressure [ CPAP ] ) Life expectancy &lt; 6 month Active RSV infection ( child signs/symptoms respiratory infection must negative RSV test ) Known renal impairment Known hepatic dysfunction Chronic seizure evolve unstable neurologic disorder Congenital heart disease [ CHD ] ( child uncomplicated CHD [ e.g. , patent ductus arterious ( PDA ) , small septal defect ] child complicate CHD currently anatomically hemodynamically normal could enrol ) Known immunodeficiency Mother HIV infection ( unless child proven infect ) Known allergy Ig product Receipt palivizumab , RSVIGIV , RSVspecific monoclonal antibody , polyclonal antibody ( example , hepatitis B IG , IVIG , VZIG ) within 3 month prior randomization Anticipated use palivizumab IVIG study ( blood transfusion permit ) Previous receipt RSV vaccine Participation investigational drug product study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Respiratory Syncytial Virus ( RSV )</keyword>
	<keyword>motavizumab</keyword>
	<keyword>palivizumab</keyword>
	<keyword>Synagis</keyword>
</DOC>